NEUPNeuphoria Therapeutics Inc.Small cap · $19.1M · FY ending 2025-06-30
$3.54+0.85% · 2026-07-10 · EOD
38/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality0
margins & F-ScoreValue76
valuation vs its own rangeMomentum27
death · price below 200-daySmart Money50
quiet · 0 funds · 0P/0S insidersBearish stackDeath crossBelow 200-day
vs S&P 500-20.3%
6-mo excess Trailing performance1M -24.0%
3M -25.0%
6M -10.8%
YTD -7.3%
1Y -52.5%
Enterprise value$-308,544.46
ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of ~21%. Annual figures from SEC XBRL.
Quiet0P / 0S insiders · 0 funds hold · 0 Congress buys
No recent insider, Congress, or fund activity on file for NEUP.
Fhealth · 13/100
May need capitalGoing-concern flagGoing-concern warning — auditor flagged substantial doubt
- ●Going-concern warning Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
- ●Active dilution shelf An effective S-3 shelf with 5 prospectus filing(s) in 12 months — shares may be getting sold into the market.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.